Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $352.1 million.

  • Kiniksa Pharmaceuticals International's Cash & Equivalents rose 57.34% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 57.34%. This contributed to the annual value of $183.6 million for FY2024, which is 70.05% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Cash & Equivalents is $352.1 million, which was up 14.40% from $307.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Cash & Equivalents high stood at $352.1 million for Q3 2025, and its period low was $108.0 million during Q4 2023.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Cash & Equivalents averaged around $222.7 million, with its median value being $213.6 million (2024).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Cash & Equivalents slumped by 44.86% in 2022 and then skyrocketed by 70.05% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents (Quarterly) stood at $122.5 million in 2021, then grew by 0.20% to $122.7 million in 2022, then decreased by 12.03% to $108.0 million in 2023, then skyrocketed by 70.05% to $183.6 million in 2024, then soared by 57.34% to $352.1 million in 2025.
  • Its last three reported values are $352.1 million in Q3 2025, $307.8 million for Q2 2025, and $268.3 million during Q1 2025.